First-Line Nivolumab and Ipilimumab vs Sunitinib in Advanced Renal Cell Carcinoma
Episode description
This week, we'll be talking about an extended follow-up of a phase III trial that investigated first-line nivolumab and ipilimumab vs sunitinib in advanced renal cell carcinoma. Then we'll go over a research letter that identified strong predictors of response to immune checkpoint inhibitor treatment. Lastly, we'll review a report on e-cigarette secondhand smoke exposure experienced by middle and high school students.
Coverage of stories discussed this week on ascopost.com:
Key Predictors of Response Rates to PD-1/PD-L1 Inhibitor Therapy Across Cancer Types
Exposure to Secondhand E-Cigarette Aerosols Increasing Among Middle and High School Students
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we'll be talking about an extended follow-up of a phase III trial that investigated first-line nivolumab and ipilimumab vs sunitinib in advanced renal cell carcinoma. Then we'll go over a research letter that identified strong predictors of response to immune checkpoint inhibitor treatment. Lastly, we'll review a report on e-cigarette secondhand smoke exposure experienced by middle and high school students.This week, we'll be talking about an extended follow-up of a phase III trial that investigated first-line nivolumab and ipilimumab vs sunitinib in advanced renal cell carcinoma. Then we'll go over a research letter that identified strong predictors of response to immune checkpoint inhibitor treatment. Lastly, we'll review a report on e-cigarette secondhand smoke exposure experienced by middle and high school students.
Coverage of stories discussed this week on ascopost.com:
Key Predictors of Response Rates to PD-1/PD-L1 Inhibitor Therapy Across Cancer Types
Exposure to Secondhand E-Cigarette Aerosols Increasing Among Middle and High School Students
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:This week, we'll be talking about an extended follow-up of a phase III trial that investigated first-line nivolumab and ipilimumab vs sunitinib in advanced renal cell carcinoma. Then we'll go over a research letter that identified strong predictors of response to immune checkpoint inhibitor treatment. Lastly, we'll review a report on e-cigarette secondhand smoke exposure experienced by middle and high school students.
Coverage of stories discussed this week on ascopost.com:
Key Predictors of Response Rates to PD-1/PD-L1 Inhibitor Therapy Across Cancer Types
Exposure to Secondhand E-Cigarette Aerosols Increasing Among Middle and High School Students
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Extended Follow-up of CheckMate 214: Nivolumab/Ipilimumab vs Sunitinib as First-Line Treatment for Advanced RCCThis week, we'll be talking about an extended follow-up of a phase III trial that investigated first-line nivolumab and ipilimumab vs sunitinib in advanced renal cell carcinoma. Then we'll go over a research letter that identified strong predictors of response to immune checkpoint inhibitor treatment. Lastly, we'll review a report on e-cigarette secondhand smoke exposure experienced by middle and high school students.
Coverage of stories discussed this week on ascopost.com:
Key Predictors of Response Rates to PD-1/PD-L1 Inhibitor Therapy Across Cancer Types
Exposure to Secondhand E-Cigarette Aerosols Increasing Among Middle and High School Students
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Key Predictors of Response Rates to PD-1/PD-L1 Inhibitor Therapy Across Cancer TypesThis week, we'll be talking about an extended follow-up of a phase III trial that investigated first-line nivolumab and ipilimumab vs sunitinib in advanced renal cell carcinoma. Then we'll go over a research letter that identified strong predictors of response to immune checkpoint inhibitor treatment. Lastly, we'll review a report on e-cigarette secondhand smoke exposure experienced by middle and high school students.
Coverage of stories discussed this week on ascopost.com:
Key Predictors of Response Rates to PD-1/PD-L1 Inhibitor Therapy Across Cancer Types
Exposure to Secondhand E-Cigarette Aerosols Increasing Among Middle and High School Students
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Exposure to Secondhand E-Cigarette Aerosols Increasing Among Middle and High School Students